Union Health Secretary addresses Annual India Leadership Summit organised by the US-India Strategic Partnership Forum in New Delhi

Smt. Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, addressed the annual India Leadership Summit 2024, organised by the US-India Strategic Partnership Forum, here today. Addressing the gathering, Smt. Punya said that India has emerged as a global leader in pharmaceuticals, being the third-largest producer and a key supplier of generic medicines. This sector's success has resulted in substantial savings for healthcare systems worldwide, including a notable contribution to the U.S. healthcare system. “The contribution of the Indian Pharmaceutical Industry is evidenced by the fact that India has the highest number of US FDA-approved pharmaceutical plants outside of the United States. This is 25% of the total number of US FDA-approved pants outside of the US. The medicines from Indian companies, I am told, provided 219 billion USD savings to the US healthcare system in 2022 and a total 1.3 Trillion USD savings between 2013 – 2022”, she stated. The country also leads in vaccine production, with a significant share of global manufacturing, underscoring its role as the “pharmacy of the world”. “50% of all vaccines manufactured in the world are from India. In the last one year alone, of the 8 billion vaccine doses manufactured and distributed across the world, 4 billion doses were manufactured in India”, she said. To ensure a robust healthcare system, the Union Health Secretary noted that India has reformed medical education, replacing outdated regulatory frameworks with the National Medical Commission Act and related laws. This has led to a significant increase in medical and nursing college numbers and enrolment, addressing disparities in healthcare professional availability”. Consequently, India is poised to produce a competent health workforce that meets both national and global needs. Smt. Punya emphasized that government efforts have progressively improved the quality, scale, and cost-effectiveness of healthcare in India. “It is a testament to our expanded healthcare services that the Out-of-pocket expenditure (OOPE), which is borne entirely by the households, has declined by 25 percentage points as a share of Total Health Expenditure between 2013-2014 and 2021-22. On the strong Indo-US Partnership in the health sector, the Union Health Secretary stated that “our mutual and shared priorities in the field of surveillance, pandemic preparedness and anti-microbial resistance are underscored in the deep partnership between National Centre for Disease Control (NCDC) and the US Centre for Disease Control & Prevention (CDC)”. “India appreciates the NCDC and ICMR Field Epidemiology Training Programs (FETP) organized in collaboration with the U.S CDC. We are happy to inform that over 200 Epidemic Intelligence Services (EIS) Officers have been trained so far with another 50 currently undergoing training through various programs”, she added. India and US have also agreed to initiate a joint strategic framework for optimizing the biopharmaceutical supply chain, for optimizing and strengthening global supply chains and to reduce dependencies on single-source suppliers, through the Bio- 5 alliance.  In 2023, Prime Minister, India and President, USA committed to accelerating the fight against cancer, leading to the inaugural U.S.-India Cancer Moonshot Dialogue launched in August. Smt. Punya highlighted that this initiative aims to enhance U.S.-India biomedical research cooperation, particularly focusing on cervical cancer. It includes partnerships with institutions like AIIMS and Tata Memorial Hospital and has evolved into the Quad Cancer Moonshot Initiative. She said that “reflecting India's vision of ‘One World, One Health,’ a grant of $7.5 million has been dedicated to cancer testing and diagnostics in the Indo-Pacific region. India will also support radiotherapy and cancer prevention efforts in the region, contributing 40 million vaccine doses under GAVI and Quad programs to assist several countries in need of these services.” Smt. Punya noted that the India-U.S. partnership in healthcare exemplifies collaborative efforts to address shared health challenges. Initiatives like the Indo-U.S. Health Dialogue have yielded tangible results in disease surveillance, pandemic preparedness, and antimicrobial resistance. Joint efforts, such as the recent U.S.-India Cancer Dialogue, focus on enhancing biomedical research and cancer prevention in the Indo-Pacific region”. She concluded her address by stating that “looking ahead, India and the U.S. can further strengthen global health security by prioritizing research, technology transfer, and capacity building. By fostering public-private partnerships and expanding collaborative vaccine initiatives, both nations can improve health outcomes”. Guided by the philosophy of ‘Vasudhaiva Kutumbakam,’ India emphasizes that global security depends on collective efforts, aiming for inclusive growth and shared well-being, she further added. *** MV HFW/ Secy addresses Annual India Leadership Summit /14 th October 2024/2   Smt. Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, addressed the annual India Leadership Summit 2024, organised by the US-India Strategic Partnership Forum, here today. Addressing the gathering, Smt. Punya said that India has emerged as a global leader in pharmaceuticals, being the third-largest producer and a key supplier of generic medicines. This sector's success has resulted in substantial savings for healthcare systems worldwide, including a notable contribution to the U.S. healthcare system. “The contribution of the Indian Pharmaceutical Industry is evidenced by the fact that India has the highest number of US FDA-approved pharmaceutical plants outside of the United States. This is 25% of the total number of US FDA-approved pants outside of the US. The medicines from Indian companies, I am told, provided 219 billion USD savings to the US healthcare system in 2022 and a total 1.3 Trillion USD savings between 2013 – 2022”, she stated. The country also leads in vaccine production, with a significant share of global manufacturing, underscoring its role as the “pharmacy of the world”. “50% of all vaccines manufactured in the world are from India. In the last one year alone, of the 8 billion vaccine doses manufactured and distributed across the world, 4 billion doses were manufactured in India”, she said. To ensure a robust healthcare system, the Union Health Secretary noted that India has reformed medical education, replacing outdated regulatory frameworks with the National Medical Commission Act and related laws. This has led to a significant increase in medical and nursing college numbers and enrolment, addressing disparities in healthcare professional availability”. Consequently, India is poised to produce a competent health workforce that meets both national and global needs. Smt. Punya emphasized that government efforts have progressively improved the quality, scale, and cost-effectiveness of healthcare in India. “It is a testament to our expanded healthcare services that the Out-of-pocket expenditure (OOPE), which is borne entirely by the households, has declined by 25 percentage points as a share of Total Health Expenditure between 2013-2014 and 2021-22. On the strong Indo-US Partnership in the health sector, the Union Health Secretary stated that “our mutual and shared priorities in the field of surveillance, pandemic preparedness and anti-microbial resistance are underscored in the deep partnership between National Centre for Disease Control (NCDC) and the US Centre for Disease Control & Prevention (CDC)”. “India appreciates the NCDC and ICMR Field Epidemiology Training Programs (FETP) organized in collaboration with the U.S CDC. We are happy to inform that over 200 Epidemic Intelligence Services (EIS) Officers have been trained so far with another 50 currently undergoing training through various programs”, she added. India and US have also agreed to initiate a joint strategic framework for optimizing the biopharmaceutical supply chain, for optimizing and strengthening global supply chains and to reduce dependencies on single-source suppliers, through the Bio- 5 alliance.  In 2023, Prime Minister, India and President, USA committed to accelerating the fight against cancer, leading to the inaugural U.S.-India Cancer Moonshot Dialogue launched in August. Smt. Punya highlighted that this initiative aims to enhance U.S.-India biomedical research cooperation, particularly focusing on cervical cancer. It includes partnerships with institutions like AIIMS and Tata Memorial Hospital and has evolved into the Quad Cancer Moonshot Initiative. She said that “reflecting India's vision of ‘One World, One Health,’ a grant of $7.5 million has been dedicated to cancer testing and diagnostics in the Indo-Pacific region. India will also support radiotherapy and cancer prevention efforts in the region, contributing 40 million vaccine doses under GAVI and Quad programs to assist several countries in need of these services.” Smt. Punya noted that the India-U.S. partnership in healthcare exemplifies collaborative efforts to address shared health challenges. Initiatives like the Indo-U.S. Health Dialogue have yielded tangible results in disease surveillance, pandemic preparedness, and antimicrobial resistance. Joint efforts, such as the recent U.S.-India Cancer Dialogue, focus on enhancing biomedical research and cancer prevention in the Indo-Pacific region”. She concluded her address by stating that “looking ahead, India and the U.S. can further strengthen global health security by prioritizing research, technology transfer, and capacity building. By fostering public-private partnerships and expanding collaborative vaccine initiatives, both nations can improve health outcomes”. Guided by the philosophy of ‘Vasudhaiva Kutumbakam,’ India emphasizes that global security depends on collective efforts, aiming for inclusive growth and shared well-being, she further added. *** MV HFW/ Secy addresses Annual India Leadership Summit /14 th October 2024/2